Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Bahlis NJ et al. Leukemia. 2017 Apr 4. doi: 10.1038/leu.2017.111. [Epub ahead of print].

Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma.
Knop S et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.124. [Epub ahead of print].

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M et al. N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
Kim MK et al. Oncotarget. 2017 Apr 3. doi: 10.18632/oncotarget.16790. [Epub ahead of print].

Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Skopec B et al. Wien Klin Wochenschr. 2017 Apr 24. doi: 10.1007/s00508-017-1205-z. [Epub ahead of print].

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration Time for Adult Stem Cell Transplantation.
Stover JT et al. Biol Blood Marrow Transplant. 2017 Apr 11. pii: S1083-8791(17)30395-6. doi: 10.1016/j.bbmt.2017.04.007. [Epub ahead of print].

Long-term follow-up of patients with multiple myeloma treated with total body irradiation – melphalan conditioning.
Munker R et al. Eur J Haematol. 2017 Mar 31. doi: 10.1111/ejh.12890. [Epub ahead of print].

Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Holmberg LA et al. Acta Haematol. 2017;137(3):123-131. doi: 10.1159/000455937. Epub 2017 Mar 30.

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
Hari P et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.122. [Epub ahead of print].

Cyclophosphamide based stem cell mobilization in relapsed multiple myeloma patients: a subgroup analysis from the phase III trial ReLApsE.
Baertsch MA et al. Eur J Haematol. 2017 Mar 31. doi: 10.1111/ejh.12888. [Epub ahead of print].

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA et al. Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.

Salvage use of allogeneic HSCT after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the EBMT Chronic Malignancies Working Party.
Sobh M et al. Haematologica. 2017 Apr 20. pii: haematol.2017.165399. doi: 10.3324/haematol.2017.165399. [Epub ahead of print].

Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
Grammatico S et al. Leuk Lymphoma. 2017 Apr 12:1-3. doi: 10.1080/10428194.2017.1307360. [Epub ahead of print].

Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD).
Sekiguchi Y et al. Int J Hematol. 2017 Mar 28. doi: 10.1007/s12185-017-2222-4. [Epub ahead of print].

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.
Cerchione C et al. Clin Case Rep. 2017 Mar 8;5(4):505-507. doi: 10.1002/ccr3.773. eCollection 2017.